Glucagon‐like peptide‐1 therapy for youth with type 2 diabetes
Young Min Cho
doaj +1 more source
Glucagon-Like Peptide-1 Targets in the Human Nodose Ganglion. [PDF]
Merchant W +3 more
europepmc +1 more source
Administrative costs of prior authorizations for glucagon-like peptide-1 agonists. [PDF]
Pham D +6 more
europepmc +1 more source
Signaling architecture of the glucagon-like peptide-1 receptor. [PDF]
Austin G, Tomas A.
europepmc +1 more source
Impact of GLP-1 Receptor Agonists on Perceived Eating Behaviors in Response to Stimuli
Carol Cheney,1 Krystal Hunter,1 Marlena Klein2 1Cooper Medical School of Rowan University, Camden, NJ, USA; 2Internal Medicine Department, Cooper University Hospital, Camden, NJ, USACorrespondence: Carol Cheney, Cooper Medical School of Rowan University,
Cheney C, Hunter K, Klein M
doaj
Oral Glucagon-Like Peptide-1 Receptor Agonists for Preventing Cardiorenal Complications. [PDF]
Odeleye V +6 more
europepmc +1 more source
Accumulation and attenuation of cardiovascular benefit with glucagon-like peptide 1 receptor agonists. [PDF]
Batty JA, Del Toro T, Hall M.
europepmc +1 more source
Distribution of glucagon-like peptide 1 receptor and insulin in phaeochromocytomas. [PDF]
Følling I +5 more
europepmc +1 more source
Glucagon-Like Peptide-1 Receptor Agonists in Obesity-Induced Respiratory Pathophysiology. [PDF]
Ruiz MA +5 more
europepmc +1 more source
Prescribing Trends in Glucagon-Like Peptide-1 Medications Among Pregnant and Postpartum Persons. [PDF]
Lessard C +12 more
europepmc +1 more source

